Estimands in SUSTAIN 8

Efficacy and safety of semaglutide vs. canagliflozin as add-on to metformin in subjects with type 2 diabetes
A phase 3b trial

Bryan Goldman and Helle Lynggaard,
Novo Nordisk A/S
29-apr-2022
Disclaimer

• Opinions are those of the presenter and are not necessarily the views of Novo Nordisk
Primary Objective in SUSTAIN 8

• To compare the effect of once-weekly dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with T2D on a background treatment of metformin.

• To confirm non-inferiority of semaglutide s.c. (1.0 mg) vs. oral canagloflozin (300 mg) with respect to change from baseline to week 52 in HbA$_{1c}$ (%-point) using a non-inferiority margin of 0.3%-point

• To confirm superiority of semaglutide s.c. (1.0 mg) vs. oral canagloflozin (300 mg) with respect to change from baseline to week 52 in HbA$_{1c}$ (%-point)
Primary Estimand in SUSTAIN 8

- Two intercurrent events (ICEs) identified
  - Treatment discontinuation for any reason
  - Use of rescue medication

- Both ICEs handled by the hypothetical strategy
Primary estimand in SUSTAIN 8

The difference between means in change from baseline HbA1c after 52 weeks, in patients with Type 2 diabetes, treated with semaglutide s.c. 1.0 mg once-weekly versus oral canagliflozin 300 mg both on a background treatment of metformin, had patients always adhered to investigational medicinal product and had rescue medication not been available.
Rationale for primary estimand

• “...considered clinically relevant as it assesses the glycaemic benefit a person with T2D is expected to achieve if initiating and continuing treatment with semaglutide compared to initiating and continuing treatment with canagliflozin both without the potential effect of rescue medication... This will avoid confounding from rescue medication.”

• Avoiding this confounding especially important in a non-inferiority setting

• In line with the primary estimand in the SUSTAIN phase 3a studies
Who decided on the estimand

- Trial Protocol finalised end 2016 (prior to release of draft ICH E9(R1))
- Driven by the statistician in alignment with
  - Phase 3a (SUSTAIN) programme of semaglutide s.c. 0.5 mg and 1.0 mg once-weekly
  - Phase 3a programme for other diabetes projects
  - As similar as possible to current practice at the time of planning the trial
- Should be driven by the clinician with strong support from statistician
Additional Estimand in SUSTAIN 8

- Two intercurrent events (ICEs) identified
  - Treatment discontinuation for any reason
  - Use of rescue medication

- Both ICEs handled by the treatment policy strategy
Additional Estimand in SUSTAIN 8

The difference between means in
change from baseline HbA1c after 52 weeks,
in patients with Type 2 diabetes,
treated with semaglutide s.c. 1.0 mg once-weekly versus oral canagliflozin 300 mg both on a background treatment of metformin, irrespectively of adherence to investigational medicinal product and with use of rescue medication as required.

Population-level summary measure
Endpoint
Population
Treatment Conditions
Strategies for Intercurrent Events
Trial Design

784 subjects with T2D
- Age ≥18 years
- HbA₁c 7.0–10.5%
- Stable dose of metformin
- eGFR ≥ 60 mL/min/1.73 m²

Trial information
- Randomised, double-blind, double dummy, active-comparator, multicentre, multinational, two-arm, parallel group trial
- Semaglutide dose escalation from 0.25 mg and doubled every 4 weeks until maintenance dose was achieved
- Canagliflozin dose escalation from 100 mg to 300 mg after 8 weeks

Semaglutide s.c. 1.0 mg + Canagliflozin placebo
Canagliflozin 300 mg + Semaglutide placebo

Treatment duration 52 weeks
Follow-up 5 weeks
Retention and Collection of Data

• Applying a hypothetical strategy

Baseline  measurement  6 months

Patient 1  • Start of rescue medication  • No intercurrent event - Treatment complete
Patient 2  • 6-month value not of interest – but could facilitate estimation

• Applying the treatment policy strategy

Patient 1  • Start of rescue medication  • No intercurrent event - Treatment complete
Patient 2  • 6-month value still considered  • Intercurrent event disregarded
Patient 3  • LTFU  • No intercurrent event - Patient included but data are missing

Legend:
- 6-month value has been collected
- 6-month value has not been collected, data are missing
- LTFU - Patient lost to follow-up

Source: E9(R1) EWG Step 4 Training Material, E9(R1) Training Material - PDF 0.pdf (ich.org)
Retention and Collection of Data are Key

• Follow-up on all randomised patients required to enable valid estimation of the additional estimand, but not for the primary
• Regulators generally prefer an estimand where all intercurrent events are handled by the treatment policy strategy
• Require full support from investigators, site staff, sponsor’s clinical operations staff
Questions?